User preferences for a contraceptive microarray patch in India and Nigeria: Qualitative research on what women want

• Published in: PloS one Vol. 14; no. 6; p. e0216797
• Main Authors: Brunie, Aurélie, Callahan, Rebecca L, Godwin, Christine L, Bajpai, Jyoti, OlaOlorun, Funmilola M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.06.2019; Public Library of Science (PLoS)
• Subjects: Acceptability; Adolescent; Adult; Analysis; Backup software; Biology and Life Sciences; Birth control; Commerce; Complications and side effects; Consumer Behavior; Contraceptive Devices - adverse effects; Contraceptive Devices - economics; Contraceptives; End users; Engineering and Technology; Exanthema; Family planning; Female; Focus Groups; Formulations; Health surveys; Humans; Immunization; India; Influenza; Low income groups; Marital status; Medicine and Health Sciences; Methods; Microtechnology - instrumentation; Middle Aged; Nigeria; Pain; Pain - etiology; People and Places; Pregnancy; Pricing; Product design; Product development; Product Packaging; Product specifications; Qualitative Research; Rash; Reproductive sterilization; Research and Analysis Methods; Safety; Skin; Skin - drug effects; Skin diseases; Time Factors; Topical analgesics; Women's health; Womens health; Young Adult; Nigeria; India; New York; Georgia; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0216797

A new contraceptive microarray patch (MAP) for women is in development. Input on this method from potential end-users early in the product development process is important to guide design decisions. This paper presents the qualitative component of a broader study exploring initial acceptability of the MAP and selected product features. The qualitative research was intended to identify product features that are most salient to end-users and to contextualize preferences around them with subsequent research planned to assess quantitatively the relative importance of those features. We conducted 16 focus group discussions and 20 in-depth interviews with women and 20 IDIs with family planning providers in New Delhi, India, and Ibadan, Nigeria. Input from the MAP developer served to identify plausible features of the MAP to include in the focus group discussions and in-depth interviews. Interviews were audio-recorded, transcribed into English, coded, and analyzed to examine key dimensions of MAP features. Many participants viewed the MAP as potentially easy to use. Interest in self-application after learning correct use was high, especially in India. Participants favored formulations affording protection from pregnancy for three or six months, if not longer. Interest in a shorter-acting MAP was particularly low in Nigeria. Non-desirable MAP features included a potential localized skin rash and pain at application. Views on patch size and location of application were related to the potential for rash and pain, with a desire to permit discreet use and minimize pain. Results indicate that the side effect profile, effectiveness, and pricing are also important factors for acceptability and uptake of a future product. Study findings indicate that a contraceptive MAP is of potential interest to women and that specific MAP attributes will be important to acceptability.